Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30
2014 ASH Annual MeetingLaurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30: Preliminary Results From a Phase II Study.”
Related Videos
Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Labe...
Sagar Lonial, MD, on the Phase III ASPIRE Trial
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 79, “Carfilzomib...
Linda J. Burns, MD, on the BLAST Study
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379,
Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementatio...
Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380,
